Clarify the Role of Paxlovid or Molnupiravir for COVID-19
February 2022
New oral antivirals will raise questions about treating COVID-19.
Recommend Paxlovid (nirmatrelvir/ritonavir) first-line for most outpatients with mild to moderate COVID-19, since it seems more effective...and molnupiravir when other options aren't available.
Eligibility. Educate that these meds are for patients with a positive COVID-19 test who are at high risk of developing severe illness (age 65 or older, diabetes, etc)...regardless of vaccination status.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote